We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Oncology

Oncology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Revolutionizing Stage II Colorectal Cancer Prognostication: Validating Semantically-Enhanced AI for Risk Stratification
Gastroenterologyprognostic biomarkersdeep learning

Revolutionizing Stage II Colorectal Cancer Prognostication: Validating Semantically-Enhanced AI for Risk Stratification

By MedXY|Aug 4, 2026

A novel AI model, SÉMIL, integrating vision-language and multiple instance learning, improves prognostic accuracy for stage II colorectal cancer by refining risk stratification beyond current clinical assessments, especially within NCCN hig

Evaluating Pemetrexed Monotherapy and Combination Therapy with Carboplatin in Advanced Thyroid Cancer: A Retrospective Cohort Analysis
Diabetes & Endocrinologythyroid cancerPemetrexed

Evaluating Pemetrexed Monotherapy and Combination Therapy with Carboplatin in Advanced Thyroid Cancer: A Retrospective Cohort Analysis

By MedXY|Aug 4, 2026

This retrospective study assesses the efficacy and safety of pemetrexed, alone or combined with carboplatin, as salvage therapy for advanced thyroid cancer, showing promising response rates comparable to current second-line treatments.

Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial
Gastroenterologyhepatocellular carcinomarandomized clinical trial

Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial

By MedXY|Jul 30, 2026

The phase 3 TORCH trial demonstrates that adding selective radiofrequency ablation after transarterial chemoembolization significantly improves progression-free and overall survival in patients with unresectable liver-confined hepatocellula

Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention: A Clinical and Economic Review
Clinical UpdatesCost-Effectivenesskeratinocyte carcinoma

Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention: A Clinical and Economic Review

By MedXY|Jul 30, 2026

Oral nicotinamide reduces keratinocyte carcinoma incidence in high-risk individuals, providing significant cost savings and quality-adjusted life-year gains, supporting its role as a cost-effective preventive strategy.

Combining Anatomical and Histologic Response Predicts Recurrence After Surgery for Colorectal Liver Metastases
Oncologycolorectal liver metastasesneoadjuvant therapy

Combining Anatomical and Histologic Response Predicts Recurrence After Surgery for Colorectal Liver Metastases

By MedXY|Jul 29, 2026

A multi-institutional study of 483 patients shows that combining macroscopic (TBSr) and histologic (TRG) response to neoadjuvant therapy better stratifies recurrence risk after hepatectomy for colorectal liver metastases than either measure alone.

MIND Diet Linked to Lower Cancer Risk and Reduced Mortality, With New Genetic Insights
CardiologyMIND dietMediterranean-DASH intervention

MIND Diet Linked to Lower Cancer Risk and Reduced Mortality, With New Genetic Insights

By MedXY|Jul 26, 2026

A meta-analysis of 23 observational studies shows higher MIND diet adherence is associated with a 55% lower cancer risk and reduced all-cause and CVD mortality. Separately, the MIND trial now provides genetic data to explore precision nutrition for cognitive decline.

Oncologyquality of lifeoncology

New EORTC Questionnaire Module for Vulvar Cancer Quality of Life Undergoes Successful Cross-Cultural Pre-Testing

By MedXY|Aug 18, 2026

The EORTC QLQ-VU34, a new disease-specific quality-of-life module for vulvar cancer patients, was developed and pre-tested across nine European countries, showing high relevance and applicability.

Enhancing Mutation Detection in NSCLC: Evaluating Concurrent EBUS-TBNA and Liquid Biopsy NGS Approaches
newsEBUS-TBNAMutation Detection

Enhancing Mutation Detection in NSCLC: Evaluating Concurrent EBUS-TBNA and Liquid Biopsy NGS Approaches

By MedXY|Jul 24, 2026

This study assesses the diagnostic benefits of concurrent EBUS-TBNA tissue sampling and liquid biopsy for next generation sequencing in NSCLC, highlighting complementary roles and implications for clinical practice.

Comparing FLOT and CROSS Protocols: Survival and Recurrence in Esophageal Adenocarcinoma with Pathological Complete Response
GastroenterologyCROSS chemoradiotherapyEsophageal Adenocarcinoma

Comparing FLOT and CROSS Protocols: Survival and Recurrence in Esophageal Adenocarcinoma with Pathological Complete Response

By MedXY|Jul 24, 2026

This cohort study compares long-term survival and recurrence in esophageal adenocarcinoma patients achieving pathological complete response (pCR) after neoadjuvant FLOT chemotherapy versus CROSS chemoradiotherapy, highlighting better outcom

Improving Quality of Life with Venting Gastrostomy Tubes in Malignant Bowel Obstruction: Insights from a Retrospective Cohort Study
General Surgerymalignant bowel obstructionpalliative surgery

Improving Quality of Life with Venting Gastrostomy Tubes in Malignant Bowel Obstruction: Insights from a Retrospective Cohort Study

By MedXY|Jul 20, 2026

Venting gastrostomy tube placement in malignant bowel obstruction is linked to improved diet tolerance, fewer vomiting episodes, and reduced antiemetic use, with successful placement achievable in over 90% of cases despite challenges.

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial
newsNon-Small Cell Lung Cancerperioperative immunotherapy

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

By MedXY|Jul 20, 2026

This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly en

Unraveling Failure to Rescue in Major Gynecologic Cancer Surgery: Insights from a NSQIP Analysis
newsGynecologic Oncology术后并发症

Unraveling Failure to Rescue in Major Gynecologic Cancer Surgery: Insights from a NSQIP Analysis

By MedXY|Aug 18, 2026

This study identifies key patient-level factors associated with failure to rescue after major gynecologic oncology surgery, emphasizing complication severity and physiological reserve over procedure complexity.

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors
newslong-term outcomesMenopause

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors

By MedXY|Aug 18, 2026

Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased onc

Targeting the IL-17/NGAL/NETs/ITGA5 Axis: A Novel Strategy to Overcome Immunosuppression and Fibroblast Reprogramming in Pancreatic Cancer
Gastroenterologycancer-associated fibroblastsimmunosuppression

Targeting the IL-17/NGAL/NETs/ITGA5 Axis: A Novel Strategy to Overcome Immunosuppression and Fibroblast Reprogramming in Pancreatic Cancer

By MedXY|Jul 20, 2026

This study unravels how tumour-derived NGAL induces NETs that reprogram fibroblast subtypes via ITGA5, promoting immunosuppression and tumour progression in pancreatic ductal adenocarcinoma, suggesting combinatorial therapies to enhance imm

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer
Gastroenterologycolorectal cancerimmune checkpoint inhibitors

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer

By MedXY|Jul 20, 2026

This study uncovers a novel DR5/Ligase 3 feedback mechanism that sustains immunogenicity and enhances immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer.

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based Review
Clinical Updatescancer treatmentCost-Effectiveness

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based Review

By MedXY|Jul 17, 2026

Medicare Advantage beneficiaries with cancer receive guideline-concordant treatment similarly to Traditional Medicare enrollees but at lower costs and comparable timeliness, highlighting implications for healthcare policy and cost-effective

EIF4A3-Driven Nonsense-Mediated Decay: A Novel Regulatory Axis Modulating AML1-ETO9a Dosage and Clinical Outcomes in t(8;21) Acute Myeloid Leukemia
Hematology-Oncologyacute myeloid leukemiaAML1-ETO9a

EIF4A3-Driven Nonsense-Mediated Decay: A Novel Regulatory Axis Modulating AML1-ETO9a Dosage and Clinical Outcomes in t(8;21) Acute Myeloid Leukemia

By MedXY|Jul 17, 2026

This review highlights how EIF4A3-dependent nonsense-mediated mRNA decay selectively regulates the oncogenic AML1-ETO9a isoform in t(8;21) AML, influencing leukemic cell proliferation, chemosensitivity, and patient survival through an isofo

Balancing Risk and Quality of Life: Factors Influencing Timing of Oophorectomy After Risk-Reducing Salpingectomy in BRCA Previvors
newsBRCAcancer risk reduction

Balancing Risk and Quality of Life: Factors Influencing Timing of Oophorectomy After Risk-Reducing Salpingectomy in BRCA Previvors

By MedXY|Jul 16, 2026

This article examines the clinical and psychosocial factors influencing BRCA previvors’ decisions on timing delayed oophorectomy after risk-reducing salpingectomy, highlighting the nuanced balance between cancer anxiety and menopausal

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment
newsCAR-T Therapyimmunotherapy

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment

By MedXY|Jul 16, 2026

This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and

Targeting SOX9-Driven SPEM Plasticity: A New Therapeutic Avenue to Prevent Gastric Cancer Progression
Gastroenterologycell plasticityGastric Cancer

Targeting SOX9-Driven SPEM Plasticity: A New Therapeutic Avenue to Prevent Gastric Cancer Progression

By MedXY|Jul 16, 2026

SOX9 is a pivotal regulator of SPEM cell plasticity driving gastric metaplasia and carcinogenesis. Therapeutically targeting SOX9 may prevent the progression of pre-cancerous lesions to gastric cancer by blocking metaplastic evolution.

Prev
9 / 25
1…7891011…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles